Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IPH6501 |
Synonyms | |
Therapy Description |
IPH6501 is a tetraspecific molecule targeting NKp46, CD16a, IL2RB (CD122), and MS4A1 (CD20), which potentially induces NK cell-mediated cytotoxicity against tumor cells (Blood (2022) 140 (Supplement 1): 11559). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IPH6501 | IPH-6501|IPH 6501 | CD20 Antibody 24 | IPH6501 is a tetraspecific molecule targeting NKp46, CD16a, IL2RB (CD122), and MS4A1 (CD20), which potentially induces NK cell-mediated cytotoxicity against tumor cells (Blood (2022) 140 (Supplement 1): 11559). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |